
Amid efforts to blunt rising medicines costs, a new analysis finds three states succeeded in helping their residents save money by capping out-of-pocket costs on pricey specialty drugs and, at the same time, also managed to avoid increased spending by health plans.
Overall, out-of-pocket spending by patients fell $351 per month in Delaware, Maryland, and Louisiana, each of which passed laws that set $150 caps on what consumers must pay for prescriptions for specialty medicines. These include medications to combat such hard-to-treat maladies as multiple sclerosis, rheumatoid arthritis, and hepatitis C, among others.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Once a patient reaches the cap, which entity absorbes the loss from the reduced co-pay contribution?
I don’ know – but I am guessing the insurers just get less out-of-pocket money from patients.